检索结果-南通市图书馆

Nuclear Science and Techniques 2021年第10期32卷 72-78页

作者： jian zhong Xiao-guang Wu Shi-Peng hu Ying-jun Ma Yun Zheng Cong-Bo Li guang-Sheng Li Bao-Ji zhu Tian-Xiao Li Yan-jun Jin Yan-Xiang Gao Qi-Wen fan Ke-Yan Ma Dong Yang hui-Bin Sun hai-Ge zhao Lin Gan Qi Luo Zheng-xin Wu College of Physics and Optoelectronic Engineering Shenzhen UniversityShenzhen 518060China China Institute of Atomic Energy Beijing 102413China College of Physics Jilin UniversityChangchun 621010China

Lifetimes of the 2_(1)^(+),4_(1)^(+),7_(2)^(-),10_(2)^(+),12_(2)^(+),and 14_(1)^(+) states in 138 Nd populated via the 123 Sb(19 F,4n)138 Nd fusion–evaporation reaction were measured with the recoil distance Doppler shift technique in combination with the differential decay curve *** B(E2;2_(1)^(+)→0_(1)^(+))value fit well with the systematic trend in the Nd isotope chain and Grodzins rule,which proved that 138Nd is a transitional nucleus.

关键词： Lifetime measurement Recoil distance Doppler shift technique Differential decay curve method

Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma(CHANCE001)

在线全文

学校读者我要写书评

暂无评论

Signal Transduction and Targeted Therapy 2023年第3期8卷 1198-1207页

作者： hai-Dong zhu hai-Liang Li Ming-Sheng huang Wei-zhu Yang Guo-Wen Yin Bin-Yan zhong jun-hui Sun Zhi-Cheng Jin jian-jian Chen Nai-jian Ge Wen-Bin Ding Wen-hui Li Jin-hua huang Wei Mu Shan-Zhi Gu Jia-Ping Li hui zhao Shu-Wei Wen Yan-Ming Lei Yu-Sheng Song Chun-Wang Yuan Wei-Dong Wang Ming huang Wei zhao jian-Bing Wu Song Wang Xu zhu jian-jun Han Wei-xin Ren Zai-Ming Lu Wen-Ge xing Yong fan hai-Lan Lin Zi-Shu Zhang Guo-hui Xu Wen-Hao hu Qiang Tu Hong-Ying Su Chuan-Sheng Zheng Yong Chen Xu-Ya zhao zhu-Ting fang Qi Wang Jin-Wei zhao Ai-Bing Xu jian Xu Qing-hua Wu huan-Zhang Niu jian Wang Feng Dai Dui-Ping Feng Qing-Dong Li Rong-Shu Shi Jia-Rui Li guang Yang hai-Bin Shi jian-Song Ji Yu-E Liu Zheng Cai Po Yang Yang zhao Xiao-Li zhu Li-Gong Lu Gao-jun Teng Center of Interventional Radiology&Vascular Surgery Department of RadiologyZhongda HospitalMedical SchoolSoutheast UniversityNanjing 210009China Department of Minimally invasive Intervention The Affiliated Cancer Hospital of Zhengzhou UniversityZhengzhou 450008China Department of Interventional Radiology the Third Affiliated HospitalSun Yat-Sen UniversityGuangzhou 510630China Department of Interventional Radiology Union Hospital of Fujian Medical UniversityFuzhou 350001China Department of Interventional Radiology Jiangsu Cancer Hospital&Jiangsu Institute of Cancer Research&The Affiliated Cancer Hospital of Nanjing Medical UniversityNanjing 210009China Department of Interventional Radiology The First Affiliated Hospital of Soochow UniversitySoochow UniversitySuzhou 215006China Hepatobiliary and Pancreatic Interventional Treatment Center Division of Hepatobiliary and Pancreatic SurgeryThe First Affiliated HospitalZhejiang University School of MedicineHangzhou 310003China Department of Interventional Radiology Eastern Hospital of Hepatobiliary SurgeryNavy Medical University(Second Military Medical University)Shanghai 200438China Department of Interventional Radiology Nantong First People’s HospitalNantong 226001China Department of Interventional Radiology Yancheng Third People’s HospitalYancheng 224008China Department of Minimally Invasive Interventional Therapy Sun YatSen University Cancer CenterGuangzhou 510060China Department of Vascular Surgery Southwest HospitalThird Military Medical University(Army Medical University)Chongqing 400038China. Department of Interventional Radiology Hunan Cancer HospitalChangsha 410031China Department of Interventional Oncology The First Affiliated Hospital of Sun Yat-sen UniversityGuangzhou 510080China Department of Interventional Radiology The Hospital of Nantong UniversityNantong 226001China Department of Interventional Therapy Shanxi Tumor HospitalTaiyuan 030001China Department of Interventional Radiology Tibet Autonomous Region People’s

There is considerable potential for integrating transarterial chemoembolization(TACE),programmed death-(ligand)1(PD-[L]1)inhibitors,and molecular targeted treatments(MTT)in hepatocellular carcinoma(HCC).It is necessary to investigate the therapeutic efficacy and safety of TACE combined with PD-(L)1 inhibitors and MTT in real-world *** this nationwide,retrospective,cohort study,826 HCC patients receiving either TACE plus PD-(L)1 blockades and MTT(combination group,n=376)or TACE monotherapy(monotherapy group,n=450)were included from January 2018 to May *** primary endpoint was progression-free survival(PFS)according to modified *** secondary outcomes included overall survival(OS),objective response rate(ORR),and *** performed propensity score matching approaches to reduce bias between two *** matching,228 pairs were included with a predominantly advanced disease *** PFS in combination group was 9.5 months(95%confidence interval[CI],8.4-11.0)versus 8.0 months(95%CI,6.6-9.5)(adjusted hazard ratio[HR],0.70,P=0.002).OS and ORR were also significantly higher in combination group(median OS,19.2[16.1-27.3]vs.15.7 months[13.0-20.2];adjusted HR,0.63,P=0.001;ORR,60.1%vs.32.0%;P<0.001).Grade 3/4 adverse events were observed at a rate of 15.8%and 7.5%in combination and monotherapy groups,*** results suggest that TACE plus PD-(L)1 blockades and MTT could significantly improve PFS,OS,and ORR versus TACE monotherapy for Chinese patients with predominantly advanced HCC in real-world practice,with an acceptable safety profile.

关键词： hepatocellular targeted matching

Detection of an anti-angina therapeutic module in the effective population treated by a multi-target drug Danhong injection:a randomized trial

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Signal Transduction and Targeted Therapy 2021年第10期6卷 3009-3018页

作者： jun Liu Dan-Dan Li Wei Dong Yu-Qi Liu Yang Wu Da-Xuan Tang Fu-Chun Zhang Meng Qiu Qi hua Jing-Yu He jun Li Bai Du Ting-hai Du Lin-Lin Niu Xue-jun jiang Bo Cui jiang-Bin Chen Yang-Gan Wang hai-Rong Wang Qin Yu Jing He Yi-Lin Mao Xiao-fang Bin Yue Deng Yu-Dan Tian Qing-hua Han Da-Jin Liu Li-Qin Duan Ming-jun zhao Cui-Ying Zhang hai-Ying Dai Ze-hua Li Ying Xiao You-Zhi hu Xiao-Yu huang Kun xing xin jiang Chao-Feng Liu Jing An Feng-Chun Li Tao Tao Jin-Fa jiang Ying Yang Yao-Rong Dong Lei Zhang guang Fu Ying Li Shu-Wei huang Li-Ping Dou Lan-jun Sun Ying-Qiang zhao Jie Li Yun Xia jun Liu fan Liu Wen-Jin He Ying Li jian-Cong Tan Yang Lin Ya-Bin Zhou jian-Fei Yang Guo-Qing Ma hui-jun Chen He-Ping Liu Zong-Wu Liu jian-Xiong Liu Xiao-Jia Luo Xiao-Hong Bin Ya-Nan Yu hai-Xia Dang Bing Li Fei Teng Wang-Min Qiao Xiao-Long zhu Bing-Wei Chen Qi-guang Chen Chun-Ti Shen Yong-Yan Wang Yun-Dai Chen zhong Wang Institute of Basic Research in Clinical Medicine China Academy of Chinese Medical SciencesBeijingChina Department of Cardiology Chinese PLA General HospitalBeijingChina Department of Cardiology Dongfang Hospital Affiliated to Beijing University of Chinese MedicineBeijingChina Department of Geratology Peking University Third HospitalBeijingChina Department of Cardiology Xuan Wu HospitalCapital Medical UniversityBeijingChina Department of Cardiology Guang'anmen HospitalChina Academy of Chinese Medical SciencesBeijingChina Department of Cardiology First Affiliated Hospital of Henan University of Chinese MedicineZhengzhouHenanChina Department of Cardiology Wuhan University Renmin HospitalWuhanHubeiChina Department of Cardiology Wuhan University Zhongnan HospitalWuhanHubeiChina Affiliated zhongshan Hospital of Dalian University DalianLiaoningChina Department of Cardiology Second Affiliated Hospital to Hunan University of Chinese MedicineChangshaHunanChina Department of Cardiology First Affiliated Hospital to Changchun University of Chinese MedicineChangchunJilinChina Department of Cardiology First Affiliated Hospital to Shanxi Medical UniversityTaiyuanShanxiChina Department of Cardiology Affiliated Hospital of Shanxi University of Chinese MedicineXianyangShanxiChina Department of Cardiology Changsha Central HospitalChangshaHunanChina Department of Cardiology Hubei Provincial Hospital of Traditional Chinese MedicineWuhanHubeiChina Department of Cardiology Shanxi Provincial People's HospitalXi'anShanxiChina Department of Cardiology Shanxi Province Hospital of Traditional Chinese MedicineXi'anShanxiChina Department of Cardiology Xi'an City Hospital of Traditional Chinese MedicineXi'anShanxiChina Department of Cardiology Shanghai Tongji HospitalShanghaiChina Department of Cardiology Shanghai Municipal Hospital of Traditional Chinese MedicineShanghaiChina Department of Cardiology The First Hospital of ChangshaChangshaHunanChina Department of Cardiology Xinhua Hospi

It's a challenge for detecting the therapeutic targets of a polypharmacological drug from variations in the responsed networks in thedfferentiated populations with complex diseases,as stable coronary heart ***,in an adaptive,31-center,randomized,double-blind trial invoving 920 patients with moderate symptomatic stable angina treated by 14-day Danhong injection(DHI),a kind of polyphamacological drug with high quality control,or placebo(0.9%saline),with 76-day following-up,we firstly confrmed that DHl couldincrease the proportion of patients with clinically significant changes on angina-frequency assessed by Seattle Angina Questionnaire(ASAQ-AF220)(12.78%at Day 30,95%confidence interval[C]5.86-19.71%,P=0.0003,13.82%at Day 6C0,95%CI 6.82-20.82%,P=0.0001and 8.95%at Day 90,95%CI 2.06-15.85%,P=0.01).We also found that there were no significant differences in new-onset major vascularevents(P=0.8502)and serious adverse events(P=0.9105)between DHl and *** performing the RNA sequencing in 62 selectedpatients,we developed a systemic modular approach tp identfy differentilly expressed modules(DEMs)of DHI with the Z_(summay)valueless than 0 compared with the control group,calculated by weighted gene co-expression network analysis(WGCNA),and sketched out thebasic framework on a modular map with 25 functional modules targeted by ***,the effective therapeutic module(ETM),defined as the highest corelation value with the phenotype alteration(SAQ-AF,the change in SAQ-AF at Day 30 from baseline)calculatedby WGCNA,was identifed in the population with the best effect(ASAQ-AF240),which is related to anticoagulation and regulation ofcholesterol *** assessed the modular flexbility of this ETM using the global topological D value based on Euclidean distance,which is corelated with phenotype alteration(r^(2):0.8204,P=0.019)by linear *** study identified the ant-angina therapeuticmodule in the effective population treated by the multi-target

关键词： angina injection sketch

The first data release(DR1) of the LAMOST regular survey

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Research in Astronomy and Astrophysics 2015年第8期15卷 1095-1124页

作者： A-Li Luo Yong-Heng zhao Gang zhao Li-Cai Deng Xiao-Wei Liu Yi-Peng Jing Gang Wang Hao-Tong Zhang jian-Rong Shi Xiang-Qun Cui Yao-Quan Chu Guo-Ping Li zhong-Rui Bai Yue Wu Yan Cai Shu-Yun Cao Zi-huang Cao Jeffrey L.Carlin hai-Yuan Chen jian-jun Chen Kun-xin Chen Li Chen Xue-Lei Chen Xiao-Yan Chen Ying Chen Norbert Christlieb Jia-Ru Chu Chen-Zhou Cui Yi-Qiao Dong Bing Du Dong-Wei fan Lei Feng jian-Ning Fu Peng Gao Xue-Fei Gong Bo-zhong Gu Yan-xin Guo Zhan-Wen Han Bo-Liang He Jin-Liang Hou Yong-hui Hou Wen Hou Hong-zhuan hu Ning-Sheng hu zhong-Wen hu Zhi-Ying huo Lei Jia fang-hua jiang Xiang jiang Zhi-Bo jiang Ge Jin Xiao Kong Xu Kong Ya-Juan Lei Ai-hua Li Chang-hua Li guang-Wei Li hai-Ning Li jian Li Qi Li Shuang Li Sha-Sha Li xin-Nan Li Yan Li Yin-Bi Li Ye-Ping Li Yuan Liang Chien-Cheng Lin Chao Liu Gen-Rong Liu Guan-Qun Liu Zhi-Gang Liu Wen-Zhi Lu Yu Luo Yin-Dun Mao Heidi Newberg Ji-jun Ni zhao-Xiang Qi Yong-jun Qi Shi-Yin Shen huo-Ming Shi Jing Song Yi-Han Song Ding-Qiang Su Hong-jun Su Zheng-Hong Tang Qing-Sheng Tao Yuan Tian Dan Wang Da-Qi Wang Feng-Fei Wang Guo-Min Wang hai Wang Hong-Chi Wang jian Wang Jia-Ning Wang jian-Ling Wang jian-Ping Wang jun-Xian Wang Lei Wang Meng-xin Wang Shou-Guan Wang Shu-Qing Wang Xia Wang Ya-Nan Wang You Wang Yue-Fei Wang You-Fen Wang Peng Wei Ming-Zhi Wei Hong Wu Ke-Fei Wu Xue-Bing Wu Yu-zhong Wu Xiao-Zheng xing Ling-Zhe Xu xin-Qi Xu Yan Xu Tai-Sheng Yan De-hua Yang hai-Feng Yang hui-Qin Yang Ming Yang Zheng-Qiu Yao Yong Yu hui Yuan hai-Bo Yuan hai-Long Yuan Wei-Min Yuan Chao Zhai En-Peng Zhang hua-Wei Zhang jian-Nan Zhang Li-Pin Zhang Wei Zhang Yong Zhang Yan-Xia Zhang Zheng-Chao Zhang Ming zhao fang Zhou Xu Zhou Jie zhu Yong-Tian zhu Si-Cheng Zou fang Zuo National Astronomical Observatories Chinese Academy of Sciences Department of Astronomy Peking University Shanghai Astronomical Observatory Chinese Academy of Sciences Nanjing Institute of Astronomical Optics & Technology National Astronomical ObservatoriesChinese Academy of Sciences University of Science and Technology of China Department of Physics Applied Physics and AstronomyRensselaer Polytechnic InstituteTroyNY 12180USA Department of Physics and Astronomy Earlham CollegeRichmondIN 47374USA Universitt Heidelberg Zentrum für AstronomieLandessternwarteKnigstuhl 1269117 HeidelbergGermany Department of Astronomy Beijing Normal University Yunnan Observatories Chinese Academy of Sciences Purple Mountain Observatory Chinese Academy of Sciences

The Large sky Area Multi-Object Fiber Spectroscopic Telescope（LAMOST） general survey is a spectroscopic survey that will eventually cover approximately half of the celestial sphere and collect 10 million spectra of stars, galaxies and QSOs. Objects in both the pilot survey and the first year regular survey are included in the LAMOST DR1. The pilot survey started in October 2011 and ended in june 2012, and the data have been released to the public as the LAMOST Pilot Data Release in August 2012. The regular survey started in September 2012, and completed its first year of operation in june 2013. The LAMOST DR1 includes a total of 1202 plates containing 2 955 336 spectra, of which 1 790 879 spectra have observed signalto-noise ratio（SNR） ≥ 10. All data with SNR ≥ 2 are formally released as LAMOST DR1 under the LAMOST data policy. This data release contains a total of 2 204 696 spectra, of which 1 944 329 are stellar spectra, 12 082 are galaxy spectra and 5017 are quasars. The DR1 not only includes spectra, but also three stellar catalogs with measured parameters： late A,FGK-type stars with high quality spectra（1 061 918 entries）, A-type stars（100 073 entries）, and M-type stars（121 522 entries）. This paper introduces the survey design, the observational and instrumental limitations, data reduction and analysis, and some caveats. A description of the FITS structure of spectral files and parameter catalogs is also provided.

关键词： techniques: spectroscopic survey—data release—catalog

CEPC Technical Design Report

在线全文

学校读者我要写书评

暂无评论

Radiation Detection Technology and Methods 2024年第1期8卷 I0003-I0016,1-1091页

作者： Waleed Abdallah Tiago Carlos Adorno de Freitas Konstantin Afanaciev Shakeel Ahmad Ijaz Ahmed Xiaocong Ai Abid Aleem Wolfgang Altmannshofer Fabio Alves Weiming An Rui An Daniele Paolo Anderle Stefan Antusch Yasuo Arai Andrej Arbuzov Abdesslam Arhrib Mustafa Ashry Sha Bai Yu Bai Yang Bai Vipul Bairathi Csaba Balazs Philip Bambade Yong Ban Tripamo Bandyopadhyay Shou-Shan Bao Desmond P.Barber Ayse Bat Varvara Batozskaya Subash Chandra Behera Alexander Belyaev Michele Bertucci Xiao-jun Bi Yuanjie Bi Tianjian Bian Fabrizio Bianchi Thomas Biekotter Michela Biglietti Shalva Bilanishvili Deng Binglin Denis Bodrov Anton Bogomyagkov Serge Bondarenko Stewart Boogert Maarten Boonekamp Marcello Borri Angelo Bosotti Vincent Boudry Mohammed Boukidi Igor Boyko Ivanka Bozovic Giuseppe Bozzi Jean-Claude Brient Anastasiia Budzinskaya Masroor Bukhari Vladimir Bytev Giacomo Cacciapaglia hua Cai Wenyong Cai Wujun Cai Yijian Cai Yizhou Cai Yuchen Cai haiying Cai huacheng Cai Lorenzo Calibbi junsong Cang Guofu Cao jianshe Cao Antoine Chance Xuejun Chang Yue Chang Zhe Chang xinyuan Chang Wei Chao Auttakit Chatrabhuti Yimin Che Yuzhi Che Bin Chen Danping Chen Fuqing Chen Fusan Chen Gang Chen Guoming Chen hua-xing Chen huirun Chen Jinhui Chen Ji-Yuan Chen Kai Chen Mali Chen Mingjun Chen Mingshui Chen Ning Chen Shanhong Chen Shanzhen Chen Shao-Long Chen Shaomin Chen Shiqiang Chen Tianlu Chen Wei Chen Xiang Chen Xiaoyu Chen xin Chen Xun Chen Xurong Chen Ye Chen Ying Chen Yukai Chen Zelin Chen Zilin Chen Gang Chen Boping Chen Chunhui Chen Hok Chuen Cheng huajie Cheng Shan Cheng Tongguang Cheng Yunlong Chi Pietro Chimenti Wen Han Chiu Guk Cho Ming-Chung Chu Xiaotong Chu Ziliang Chu Guglielmo Coloretti Andreas Crivellin Hanhua Cui Xiaohao Cui zhaoyuan Cui Brunella D'Anzi Ling-Yun Dai xinchen Dai Xuwen Dai Antonio De Maria Nicola De Filippis Christophe De La Taille Francesca De Mori Chiara De Sio Elisa Del Core Shuangxue Deng Wei-Tian Deng Zhi Deng Ziyan Deng Bhupal Dev Tang Dewen Biagio Di Micco Ran Ding Siqin Dingl Yadong Ding haiyi Dong jianin AGH University of Science and Technology Faculty of Physics and Applied Computer ScienceKrakow Anhui University HefeiAnhui Applied Physics Department Federal Urdu University of ArtsScience and TechnologyIslamabad Banaras Hindu University Institute of ScienceVaranasi Bandirma Onyedi Eylul University Bandirma Beihang University Beijing Beijing Computational Science Research Center Beijing Beijing Conveyi LTD Beijing Beijing Glass Research Institute Co. LtdBeijing Beijing Institute of Technology Beijing Beijing Normal University Beijing Brown University ProvidenceRI Budker Institute of Nuclear Physics Novosibirsk Cadi Ayyad University Laboratory of Fundamental and Applied PhysicsPolydisciplinary FacultyMarrakech Cairo University Giza Center for Theory and Computation National Tsing Hua UniversityHsinchu Central China Normal University WuhanHubei Central South University ChangshaHunan Centro de Fisica Teorica de Particulas Universidade Tecnica de LisboaLisboa Chengdu KaitengSifang Digital Radio&TV Equipment Co. LtdChengduSichuan China academy of engineering physics MianyangSichuan China building materials academy Beijing China Center of Advanced Science and Technology Beijing China Institute of Atomic Energy Beijing China Jiliang University HangzhouZhejiang China Nuclear Instrument CO. LTDBeijing China University of Geosciences Beijing China University of Geosciences WuhanHubei China University of Mining and Technology XuzhouJiangsu China West Normal University NanchongSichuan Chongqing University Department of PhysicsChongqing Chulalongkorn University Bangkok City University of Hong Kong Department of PhysicsHong Kong Cockcroft Institute Daresbury Cornell University IthacaNY CPPM(AMU/IPhu&CNRS/INP) Marseille Dalian Minzu University DalianLiaoning Dalian University of Technology Department of PhysicsDalian Deutsches Elektronen-Synchrotron DESY Hamburg Dzhelepov Laboratory of Nuclear Problems of Joint Institute for Nuclear Research(DLNP JINR) Dubna East China University Of Science And Technol

The Circular Electron Positron Collider(CEPC)is a large scientific project initiated and hosted by China,fostered through extensive collaboration with international *** complex comprises four accelerators:a 30 GeV Linac,a 1.1 GeV Damping Ring,a Booster capable of achieving energies up to 180 GeV,and a Collider operating at varying energy modes(Z,W,H,and tt).The Linac and Damping Ring are situated on the surface,while the subterranean Booster and Collider are housed in a 100 km circumference underground tunnel,strategically accommodating future expansion with provisions for a potential Super Proton Proton Collider(SPPC).The CEPC primarily serves as a Higgs *** its baseline design with synchrotron radiation(SR)power of 30 MW per beam,it can achieve a luminosity of 5×10^(34)cm^(-2)s^(-1)per interaction point(IP),resulting in an integrated luminosity of 13 ab^(-1)for two IPs over a decade,producing 2.6 million Higgs *** the SR power to 50 MW per beam expands the CEPC's capability to generate 4.3 million Higgs bosons,facilitating precise measurements of Higgs coupling at sub-percent levels,exceeding the precision expected from the HL-LHC by an order of *** Technical Design Report(TDR)follows the Preliminary Conceptual Design Report(Pre-CDR,2015)and the Conceptual Design Report(CDR,2018),comprehensively detailing the machine's layout,performance metrics,physical design and analysis,technical systems design,R&D and prototyping efforts,and associated civil engineering ***,it includes a cost estimate and a preliminary construction timeline,establishing a framework for forthcoming engineering design phase and site selection *** is anticipated to begin around 2027-2028,pending government approval,with an estimated duration of 8 *** commencement of experiments and data collection could potentially be initiated in the mid-2030s.

关键词： initiated exceeding precise

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

注射用丹参多酚酸盐的临床应用综合评价

中国药学杂志 2021年第6期56卷 507-514页

作者：韩晟赵熙子史录文林丽开李大魁陈凯先宣利江马传江马海英方唯一王丽霞文爱东付秀娟左燕刘小玲刘向红刘国强朱珠陈万生陈维红吴方建吴玉波吴晖张伟张毕奎林慧周国华欧阳荣胡元会姜明燕赵春景贾乐川晋月萍唐洪梅曹俊岭梁春商洪才董占军董吁钢翟所迪北京大学医药管理国际研究中心北京100191 武汉大学中南医院武汉大学医院管理研究所武汉430071 北京协和医院北京100730 中国科学院上海药物研究所上海201203 山东中医药大学附属医院济南250014 中国医科大学附属第四医院沈阳110000 复旦大学附属华东医院上海200030 中国中医科学院广安门医院北京100053 中国人民解放军空军军医大学第一附属医院西安710032 吉林大学第二医院长春130041 陕西省人民医院西安710068 内蒙古自治区人民医院呼和浩特010017 山东大学齐鲁医院济南250012 河北医科大学第三医院石家庄050051 海军军医大学第二附属医院上海200003 山西白求恩医院(山西医学科学院) 太原030032 长江航运总医院武汉430015 哈尔滨医科大学附属第四医院哈尔滨150001 昆明医科大学第一附属医院昆明650032 河南省人民医院郑州450003 中南大学湘雅二医院长沙410011 海南省药学会海口570102 南京大学医学院附属金陵医院南京210000 湖南中医药大学第一附属医院长沙410007 中国医科大学附属第一医院沈阳110001 重庆医科大学附属第二医院重庆400010 宁夏医科大学总医院银川750004 山西医科大学第一医院太原030001 广州中医药大学第一附属医院广州510405 北京中医药大学东方医院北京100078 北京中医药大学东直门医院北京100007 河北省人民医院石家庄050051 中山大学附属第一医院广州510080 北京大学第三医院北京100191

目的以注射用丹参多酚酸盐为例,探索中药注射剂临床应用的综合评价方法,为今后相关工作的开展和完善提供参考。方法通过文献检索和获取相关文献资料,从有效性、安全性、经济性、顺应性和标签信息等方面对注射用丹参多酚酸盐进行系统综... 详细信息

目的以注射用丹参多酚酸盐为例,探索中药注射剂临床应用的综合评价方法,为今后相关工作的开展和完善提供参考。方法通过文献检索和获取相关文献资料,从有效性、安全性、经济性、顺应性和标签信息等方面对注射用丹参多酚酸盐进行系统综合评价。结果除说明书适应证外,丹参多酚酸盐在心血管疾病、脑血管疾病等多种超说明书适应证中都存在具有一定质量的临床研究证据;在安全性、经济性方面的文献证据较为丰富。结论注射用丹参多酚酸盐在有效性、安全性及经济性等方面的临床研究证据较多,且具有一定的体系。但作为一个临床应用大品种,该药依然需要在一些方面做出更多的研究努力。

关键词：丹参酚酸B镁药品综合评价中药注射剂有效性安全性

在线全文

学校读者我要写书评

暂无评论

注射用丹参多酚酸盐的药学综合评价

中国药学杂志 2021年第5期56卷 422-428页

作者：韩晟赵熙子史录文林丽开李大魁陈凯先宣利江马传江马海英方唯一王丽霞文爱东付秀娟左燕刘小玲刘向红刘国强朱珠陈万生陈维红吴方建吴玉波吴晖张伟张毕奎林慧周国华欧阳荣胡元会姜明燕赵春景贾乐川晋月萍唐洪梅曹俊岭梁春商洪才董占军董吁钢翟所迪北京大学医药管理国际研究中心北京100191 武汉大学中南医院武汉大学医院管理研究所武汉430071 北京协和医院北京100730 中国科学院上海药物研究所上海201203 山东中医药大学附属医院济南250014 中国医科大学附属第四医院沈阳110000 复旦大学附属华东医院上海200030 中国中医科学院广安门医院北京100053 中国人民解放军空军军医大学第一附属医院西安710032 吉林大学第二医院长春130041 陕西省人民医院西安710068 内蒙古自治区人民医院呼和浩特010017 山东大学齐鲁医院济南250012 河北医科大学第三医院石家庄050051 上海长征医院上海200003 山西白求恩医院(山西医学科学院) 太原030032 长江航运总医院武汉430015 哈尔滨医科大学附属第四医院哈尔滨150001 昆明医科大学第一附属医院昆明650032 河南省人民医院郑州450003 中南大学湘雅二医院长沙410011 海南省药学会海口570102 南京大学医学院附属金陵医院南京210000 湖南中医药大学第一附属医院长沙410007 中国医科大学附属第一医院沈阳110001 重庆医科大学附属第二医院重庆400000 宁夏医科大学总医院宁夏750004 山西医科大学第一医院太原030001 广州中医药大学第一附属医院广州510405 北京中医药大学东方医院北京100078 北京中医药大学东直门医院北京100007 河北省人民医院石家庄050051 中山大学附属第一医院广州510080 北京大学第三医院北京100191

目的以注射用丹参多酚酸盐为例,探索中药注射剂的综合评价方法,为今后相关工作的开展和完善提供参考。方法通过文献检索和获取相关文献资料,从药学特性、质量等方面对注射用丹参多酚酸盐进行药学综合评价。结果在有效成分和药物作用机... 详细信息

目的以注射用丹参多酚酸盐为例,探索中药注射剂的综合评价方法,为今后相关工作的开展和完善提供参考。方法通过文献检索和获取相关文献资料,从药学特性、质量等方面对注射用丹参多酚酸盐进行药学综合评价。结果在有效成分和药物作用机制方面,丹参多酚酸盐已经进行了大量的基础研究。质量方面的文献证据也较为丰富。结论注射用丹参多酚酸盐在药学特性方面研究探索面非常广,相关基础研究还有待进一步探索。

关键词：丹参酚酸B 综合评价中药注射剂药学特性

在线全文

学校读者我要写书评

暂无评论

肺癌脑(膜)转移诊断治疗共识

循证医学 2018年第4期18卷 193-201页

作者：吴一龙刘晓晴毛伟敏王启鸣冯继锋刘安文胡艳萍陈海泉杨学宁揣少坤陆舜陈明许林黄飚杨衿记周建英董晓荣徐世东崔久嵬阎海王长利周彩存王绿化江本元张力宋启斌陈克能赵琼牟巨伟廖美琳陈晓媛王洁张绪超胡成平朱广迎张真发王丽萍周德祥管忠震程颖黄诚周清华陈丽昆傅小龙宋勇陈元李强钟文昭孙浩范云伍钢陈椿刘云鹏周清蔡修宇韩宝惠涂海燕王群赵明芳杨帆邬麟胡洁常建华黄云超马智勇李峻岭乔贵宾广东省人民医院广东省医学科学院广东省肺癌研究所广州510080 中国人民解放军307医院北京100071 浙江省肿瘤医院杭州310022 河南省肿瘤医院郑州450003 江苏省肿瘤医院南京210009 南昌大学第二附属医院南昌330006 湖北省肿瘤医院武汉430079 复旦大学附属肿瘤医院上海200032 广州燃石医学检验有限公司广州510300 上海交通大学附属胸科医院上海200030 浙江大学附属第一医院杭州310003 华中科技大学同济医学院附属协和医院武汉430022 哈尔滨医科大学附属肿瘤医院哈尔滨150081 吉林大学第一医院长春130021 北京泛生子基因科技有限公司北京102206 天津医科大学肿瘤医院天津300060 同济大学附属上海市肺科医院上海200433 深圳市肿瘤医院广东深圳675000 北京协和医院北京100730 中山大学肿瘤防治中心广州510060 武汉大学人民医院武汉430060 北京大学临床肿瘤学院北京100036 中国医学科学院肿瘤医院北京100021 国家食品药品监督管理总局北京100038 中南大学湘雅医院长沙410008 中日友好医院北京100029 郑州大学附属第一医院郑州450003 吉林省肿瘤医院长春130021 福建省肿瘤医院福州350014 四川大学华西医院成都610041 南京军区南京总医院南京210002 华中科技大学同济医学院附属同济医院武汉430030 四川省肿瘤医院成都610041 武汉协和肿瘤医院武汉430023 福建医科大学附属协和医院福州350001 中国医科大学附属第一医院沈阳110001 复旦大学附属中山医院上海200032 北京大学人民医院北京100044 湖南省肿瘤医院长沙410013 云南省肿瘤医院昆明650118

2018年3月8?9日,中国临床肿瘤学会(Chinese Society of Clinical Oncology,CSCO)和中国抗癌协会肺癌专业委员会联合主办了第15届“中国肺癌高峰论坛”。本次论坛的主题为“聚焦中枢神经系统转移:精确诊断,精准治疗”。晚期肺癌患者往往... 详细信息

2018年3月8?9日,中国临床肿瘤学会(Chinese Society of Clinical Oncology,CSCO)和中国抗癌协会肺癌专业委员会联合主办了第15届“中国肺癌高峰论坛”。本次论坛的主题为“聚焦中枢神经系统转移:精确诊断,精准治疗”。晚期肺癌患者往往合并脑转移,在1 000多例的肺癌尸检结果中,肺癌脑转移发生率23%~36%,是脑转移性肿瘤中最常见的类型,且通常预后较差[1]。目前肺癌脑(膜)转移的综合治疗管理和治疗结果,仍不令人满意,治疗效果不佳,中位总生存时间16个月,其中脑膜转移的患者则仅为4.5个月左右[2?5]。近10年肺癌的治疗出现了革命性的改变,但肺癌脑转移的诊断和治疗成了提高肺癌长期生存率的瓶颈。临床医师及科研工作者,应如何对脑转移进行准确及时的诊断?在众多的分型分类体系中,又该如何参考应用?如何全面地对脑转移患者的颅内/颅外病灶进行合理评估?对于伴有驱动基因敏感突变的脑转移患者群体,应怎样对待酪氨酸激酶抑制剂(tyrosine kinase inhibitor,TKI)治疗的定位和应用时机?随着血管生成抑制剂和免疫检查点Checkpoint抑制剂的应用发展,新的治疗选择在肺癌脑转移治疗应用中又该如何管理?以上都是肺癌脑转移综合管理中的疑点和难点,急需解答和形成共识以指导临床实践。本次肺癌高峰论坛,综合近年来发表的前瞻性及回顾性重要研究结果、结合我国肺癌脑转移治疗管理的实际情况,与会专家们就肺癌脑转移的综合管理进行了详细的讨论和各抒己见的争辩,最后达成了以下四点共识。

关键词：肺肿瘤脑转移循证医学共识